Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome

被引:88
|
作者
Krejsgaard, T. [1 ,2 ]
Odum, N. [2 ]
Geisler, C.
Wasik, M. A. [3 ]
Woetmann, A. [2 ]
机构
[1] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Panum Inst, DK-2200 Copenhagen N, Denmark
[2] Univ Copenhagen, Dept Biol, DK-2200 Copenhagen N, Denmark
[3] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
cutaneous T-cell lymphoma; Sezary syndrome; immunodeficiency; regulatory T cells; FOXP3; mycosis fungoides; TUMOR-INFILTRATING LYMPHOCYTES; GROWTH-FACTOR-BETA; NF-KAPPA-B; FOXP3; EXPRESSION; FAS-LIGAND; CONSTITUTIVE ACTIVATION; MALIGNANT PROLIFERATION; CD127; LYMPHOMA-CELLS; RECEPTOR;
D O I
10.1038/leu.2011.237
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cutaneous T-cell lymphoma (CTCL) is the term for diseases characterized by primary accumulation of malignant T cells in the skin. Patients with the two predominant clinical forms of CTCL called mycosis fungoides (MF) and Sezary syndrome (SS) characteristically develop severe immunodeficiency during disease progression and consequently patients with advanced disease frequently die of infections and not from the tumor burden. For decades, it has been suspected that the malignant T cells actively drive the evolving immunodeficiency to avoid antitumor immunity, yet, the underlying mechanisms remain unclear. The identification of a subset of highly immunosuppressive regulatory T cells (Tregs) triggered a variety of studies investigating if MF and SS are malignant proliferations of Tregs but seemingly discordant findings have been reported. Here, we review the literature to clarify the role of Tregs in MF and SS and discuss the potential mechanisms driving the immunodeficiency. Leukemia (2012) 26, 424-432; doi:10.1038/leu.2011.237; published online 9 September 2011
引用
收藏
页码:424 / 432
页数:9
相关论文
共 50 条
  • [21] Mycosis fungoides, Sezary syndrome or T-cell prolymphocytic leukemia?
    Pulini, S
    Rupoli, S
    Anna, R
    Tassetti, A
    Goteri, G
    Bartocci, C
    Discepoli, G
    Mulattieri, S
    Brunori, M
    Leoni, P
    BLOOD, 2005, 106 (11) : 248B - 248B
  • [22] Bexarotene therapy for mycosis fungoides and Sezary syndrome
    Abbott, R. A.
    Whittaker, S. J.
    Morris, S. L.
    Russell-Jones, R.
    Hung, T.
    Bashir, S. J.
    Scarisbrick, J. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (06) : 1299 - 1307
  • [23] The biomarker landscape in mycosis fungoides and Sezary syndrome
    Dulmage, Brittany
    Geskin, Larisa
    Guitart, Joan
    Akilov, Oleg E.
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (08) : 668 - 676
  • [24] Is smoking associated with mycosis fungoides and Sezary syndrome?
    Chang, H. -C.
    Tsai, T. -Y.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (05) : E381 - E384
  • [25] Mycosis fungoides and Sezary syndrome - Review and outlook
    Latzka, Johanna
    Trautinger, Franz
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 (04): : 391 - 392
  • [26] TOX Expression in Mycosis Fungoides and Sezary Syndrome
    Pileri, Alessandro
    Cavicchi, Martina
    Bertuzzi, Clara
    Righi, Simona
    Zengarini, Corrado
    Sabattini, Elena
    Roncador, Giovanna
    Agostinelli, Claudio
    DIAGNOSTICS, 2022, 12 (07)
  • [27] MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME
    GISSELBRECHT, C
    DUBERTRET, L
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1993, 35 (01): : 73 - 75
  • [29] Tumor microenvironment in mycosis fungoides and Sezary syndrome
    Gonzalez, Belen Rubio
    Zain, Jasmine
    Rosen, Steven T.
    Querfeld, Christiane
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (01) : 88 - 96
  • [30] Cardiovascular risk in mycosis fungoides and sezary syndrome
    Prieto-Barrios, M.
    Tambone, S.
    Lora, D.
    Maronas-Jimenez, L.
    Rodriguez-Peralto, J.
    Ortiz-Romero, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (09) : B6 - B6